2024 Global Infectious Disease Testing Market for 100 Tests: US, Europe, Japan--Supplier Shares and Strategies, Technology and Instrumentation Review, Emerging Opportunities

This comprehensive seven-country report contains 1,954 pages, 824 tables, and is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.The report provides market segmentation analysis of over 100 diseases and viruses in seven countries; assessment of emerging technologies; review of current instrumentation; as well as strategic profiles of leading suppliers and recent market entrants with innovative technologies and products.Infectious Diseases Analyzed in the ReportAIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes, Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus, Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.Geographic Coverage%li%France%li%Germany%li%Italy%li%Japan%li%Spain%li%UK%li%USMarket Segmentation Analysis%li%Sales and market shares of major suppliers of infectious disease diagnostic products, by country and individual test.%li%Test and sales forecasts for over 90 infectious disease diagnostic assays by country, individual test and market segment: %li%Hospitals %li%Blood Banks %li%Commercial/Private Laboratories %li%Physician Offices/Group Practices %li%Public Health Laboratories%li%Review of market dynamics, trends, structure, size, growth and major suppliers by country.Current and Emerging Products%li%In-depth examination of over 90 major diseases, including etiology, current diagnostic tests, vaccines, drugs and market needs.%li%Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.Technology Review%li%Assessment of molecular diagnostic, monoclonal antibody, immunoassay,& and other technologies and their potential applications for infectious disease testing.%li%Extensive listings of companies developing or marketing infectious disease diagnostic products worldwide by individual test.Competitive Assessments%li%Detailed strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.Worldwide Market Overview%li%Estimated universe of laboratories performing infectious disease testing by country.%li%Test volume and sales projections for major infectious disease diagnostic assays by country.Opportunities and Strategic Recommendations%li%Emerging opportunities for new instrumentation, reagents, IT and other products with significant market appeal during the next five years.%li%Design criteria for decentralized testing products.%li%Alternative market penetration strategies.%li%Potential market entry barriers and risks.Contains 1,954 pages and 824 tables
I. Introduction
II. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized
Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Overview of Major Tests,
Technologies, and Instrumentation
A. Major Infectious Disease Tests
1. AIDS: HIV/HIV-1/2/COMBO, HIVAG/HIV NAT,
Western Blot, HTLV-I/II
2. ADENOVIRUS
3. AEROMONAS
4. ANTHRAX/BACILLUS ANTHRACIS
5. ARBOVIRUSES
6. BABESIOSIS
7. BACILLARY EPITHELIOID ANGIOMATOSIS (BEA)
and Other Bartonella (Rochalimaea)
8. BLASTOCYSTIS HOMINIS
9. BRUCELLA
10. CAMPYLOBACTER
11. CANDIDA
Table of Contents (continued)
12. CHAGAS DISEASE
13. CHANCROID
14. CHLAMYDIA
15. CLOSTRIDIUM DIFFICILE
16. CORONAVIRUSES
17. COXSACKIEVIRUSES
18. CREUTZFELDT-JAKOB’S DISEASE
19. CRYPTOSPORIDIUM PARVUM
20. CYCLOSPORA CAYETANENSIS
21. CYTOMEGALOVIRUS
22. EBOLA VIRUS
23. E. COLI
24. ECHOVIRUS
25. ENCEPHALITIS
26. ENTEROVIRUSES
27. EPSTEIN-BARR VIRUS
28. GIARDIA LAMBLIA
29. GONORRHEA
30. GRANULOMA INGUINALE
31. HANTAVIRUS
32. HELICOBACTER PYLORI
33. HEPATITIS: HAV NAT, HBV NAT, HBS AG, HCV, HCV NAT,
Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag,
HBe Ag, ALT/SGPT
34. HERPES SIMPLEX VIRUS
35. HUMAN HERPES VIRUS-6 (HHV-6)
36. INFLUENZA VIRUSES
37. LEGIONELLA
38. LYME DISEASE
39. LYMPHOGRANULOMA VENEREUM (LGV)
40. MALARIA
41. MEASLES (RUBEOLA)
42. MENINGITIS
43. MICROSPORIDIUM
44. MONONUCLEOSIS
45. MUMPS
46. MYCOPLASMA
47. PAPILLOMAVIRUSES
48. PARVOVIRUS B19
49. PNEUMONIA
50. POLYOMAVIRUSES
51. PSEUDOMONAS AERUGINOSA
52. RABIES
53. RESPIRATORY SYNCYTIAL VIRUS (RSV)
54. RHINOVIRUSES
55. ROTAVIRUS
II. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized
Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Overview of Major Tests,
Technologies, and Instrumentation
A. Major Infectious Disease Tests
1. AIDS: HIV/HIV-1/2/COMBO, HIVAG/HIV NAT,
Western Blot, HTLV-I/II
2. ADENOVIRUS
3. AEROMONAS
4. ANTHRAX/BACILLUS ANTHRACIS
5. ARBOVIRUSES
6. BABESIOSIS
7. BACILLARY EPITHELIOID ANGIOMATOSIS (BEA)
and Other Bartonella (Rochalimaea)
8. BLASTOCYSTIS HOMINIS
9. BRUCELLA
10. CAMPYLOBACTER
11. CANDIDA
Table of Contents (continued)
12. CHAGAS DISEASE
13. CHANCROID
14. CHLAMYDIA
15. CLOSTRIDIUM DIFFICILE
16. CORONAVIRUSES
17. COXSACKIEVIRUSES
18. CREUTZFELDT-JAKOB’S DISEASE
19. CRYPTOSPORIDIUM PARVUM
20. CYCLOSPORA CAYETANENSIS
21. CYTOMEGALOVIRUS
22. EBOLA VIRUS
23. E. COLI
24. ECHOVIRUS
25. ENCEPHALITIS
26. ENTEROVIRUSES
27. EPSTEIN-BARR VIRUS
28. GIARDIA LAMBLIA
29. GONORRHEA
30. GRANULOMA INGUINALE
31. HANTAVIRUS
32. HELICOBACTER PYLORI
33. HEPATITIS: HAV NAT, HBV NAT, HBS AG, HCV, HCV NAT,
Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag,
HBe Ag, ALT/SGPT
34. HERPES SIMPLEX VIRUS
35. HUMAN HERPES VIRUS-6 (HHV-6)
36. INFLUENZA VIRUSES
37. LEGIONELLA
38. LYME DISEASE
39. LYMPHOGRANULOMA VENEREUM (LGV)
40. MALARIA
41. MEASLES (RUBEOLA)
42. MENINGITIS
43. MICROSPORIDIUM
44. MONONUCLEOSIS
45. MUMPS
46. MYCOPLASMA
47. PAPILLOMAVIRUSES
48. PARVOVIRUS B19
49. PNEUMONIA
50. POLYOMAVIRUSES
51. PSEUDOMONAS AERUGINOSA
52. RABIES
53. RESPIRATORY SYNCYTIAL VIRUS (RSV)
54. RHINOVIRUSES
55. ROTAVIRUS